EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Jatinder Kaur Mukker, Paul Matthias Diderichsen iD, Farina Hellmann, Timothy A Yap iD, Ruth Plummer, Anthony W Tolcher, Johann S de Bono, Ioannis Gounaris iD, Zoltan Szucs, Astrid Zimmermann, Irina Kareva iD, Jayaprakasam Bolleddula und 9 weitere

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Jatinder Kaur Mukker und 20 weiteren Autor:innen. Beteiligte Einrichtung: EMD Serono, Billerica, Massachusetts, USA. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, Protein Kinase Inhibitors, Pyrazoles, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153). A population PK (POPPK) model was developed to characterize PK and hemoglobin (HGB) reduction after multicycle treatment was simulated using a semi‐mechanistic, multivariate POPPK/PD model of reticulocyte (RET), red blood cell (RBC), and HGB dynamics. A semi‐mechanistic PK‐efficacy model characterized concentration‐dependent tumor growth inhibition (TGI) in ARID1A mutant xenograft models. The clinical exposure‐PD relationship was described for phosphorylated Ser‐139 residue of the histone variant H2AX (γH2AX) as a biomarker of ATR inhibition. POPPK simulations predict the average steady‐state concentrations to exceed phosphorylated checkpoint kinase 1 (pCHK1) IC 90 at 100–180 mg once daily (QD) and 180 mg QD 2 weeks (w) on/1w off. Exposure‐related PD suggested target engagement of ≥80% at ≥130 mg QD. POPPK/PD modeling showed partial HGB recovery and lower rates of Grade ≥3 anemia after multicycle treatment with 180 mg QD 2w on/1w off vs. 130 mg and 180 mg QD. Lesser HGB reduction was predicted for 100 mg QD vs. higher QD doses. Translational modeling indicated no effect of the one‐week dosing break on TGI at 180 mg QD. The analysis supports tuvusertib 180 mg QD 2w on/1w off as the RDE and 100 mg QD as the no‐regret dose for clinical evaluation. This example underscores the value of integrated quantitative pharmacology analyses to inform dose selection using a totality of evidence approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia Telangiectasia Mutated ProteinsProtein Kinase InhibitorsPyrazolesNeoplasmsAntineoplastic AgentsHumansModels, BiologicalDose-Response Relationship, DrugAnimalsHemoglobinsXenograft Model Antitumor AssaysMaleAdministration, Oral

Substanzen

Ataxia Telangiectasia Mutated ProteinsATR protein, humanProtein Kinase InhibitorsPyrazolesHemoglobinsAntineoplastic Agents

Autor:innen und Institutionen

  • EMD Serono, Billerica, Massachusetts, USA.
  • Certara USA, Inc., Radnor, Pennsylvania, USA.
  • Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, UK.
  • Clinical Research, New Experimental Therapeutics (NEXT), San Antonio, Texas, USA.
  • Division of Clinical Studies, Royal Marsden Hospital, Sutton, UK.

ORCID-Profile: Paul Matthias Diderichsen, Timothy A Yap, Ioannis Gounaris, Irina Kareva, Christine Hicking, Wei Gao, Rainer Strotmann, Karthik Venkatakrishnan

Zitieren

APA

Mukker, J. K., Diderichsen, P. M., Hellmann, F., Yap, T. A., Plummer, R., Tolcher, A. W., de Bono, J. S., Gounaris, I., Szucs, Z., Zimmermann, A., Kareva, I., Bolleddula, J., Seithel-Keuth, A., Locatelli, G., Enderlin, M., Hicking, C., Zutshi, A., Gao, W., Strotmann, R., …, & Venkatakrishnan, K. (2026). Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70029

Vancouver

Mukker JK, Diderichsen PM, Hellmann F, Yap TA, Plummer R, Tolcher AW, et al. Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70029

BibTeX
@article{Mukker2026,
  author = {Mukker, Jatinder Kaur and Diderichsen, Paul Matthias and Hellmann, Farina and Yap, Timothy A and Plummer, Ruth and Tolcher, Anthony W and de Bono, Johann S and Gounaris, Ioannis and Szucs, Zoltan and Zimmermann, Astrid and Kareva, Irina and Bolleddula, Jayaprakasam and Seithel-Keuth, Annick and Locatelli, Giuseppe and Enderlin, Marta and Hicking, Christine and Zutshi, Anup and Gao, Wei and Strotmann, Rainer and Benincosa, Lisa and Venkatakrishnan, Karthik},
  title = {Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70029}
}
Kostenlos starten →